HC Wainwright Reaffirms “Buy” Rating for Enlivex Therapeutics (NASDAQ:ENLV)

HC Wainwright reiterated their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a report released on Monday, Benzinga reports. They currently have a $6.00 price objective on the stock. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.14) EPS and FY2025 earnings at ($0.58) EPS.

Separately, EF Hutton Acquisition Co. I upgraded Enlivex Therapeutics to a strong-buy rating in a research note on Tuesday, August 27th.

Enlivex Therapeutics Trading Up 2.5 %

Shares of NASDAQ:ENLV opened at $1.30 on Monday. The stock has a fifty day simple moving average of $1.31 and a two-hundred day simple moving average of $1.93. The stock has a market capitalization of $27.13 million, a price-to-earnings ratio of -0.94 and a beta of 1.03. Enlivex Therapeutics has a 12-month low of $1.15 and a 12-month high of $4.59.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings data on Friday, August 30th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. As a group, equities research analysts predict that Enlivex Therapeutics will post -0.81 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Enlivex Therapeutics stock. XTX Topco Ltd purchased a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 24,820 shares of the company’s stock, valued at approximately $35,000. XTX Topco Ltd owned about 0.12% of Enlivex Therapeutics at the end of the most recent reporting period. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.